The Natural Products Association (NPA) has issued a statement on the President’s FY 2023 Budget Request to Congress regarding the section on the U.S. Food and Drug Administration (FDA).
“FDA’s proposal to include mandatory product listing in their FY23 budget request is a non-starter," said Dr. Daniel Fabricant, the association's president and CEO. "Year after year, FDA receives more funding, including a $2 million increase in FY22. Yet, despite these increases, FDA consistently does less with more. Mandatory product listing is pre-market approval disguised as transparency and would only add to the bureaucratic nightmare the industry is experiencing with NAC and CBD.”
For more information, visit www.npanational.org.
The Natural Products Association (NPA) has issued a statement on the President’s FY 2023 Budget Request to Congress regarding the section on the U.S. Food and Drug Administration (FDA).
“FDA’s proposal to include mandatory product listing in their FY23 budget request is a non-starter," said Dr. Daniel Fabricant, the association's president and CEO. "Year after year, FDA receives more funding, including a $2 million increase in FY22. Yet, despite these increases, FDA consistently does less with more. Mandatory product listing is pre-market approval disguised as transparency and would only add to the bureaucratic nightmare the industry is experiencing with NAC and CBD.”
Follow Us